Daily News Podcast

Esketamine gets the green light for depression

Publish date: March 7, 2019

 

The FDA approves intranasal esketamine for refractory major depressive disorder. A behavioral intervention improves physical activity in patients with diabetes. Groups of physicians produce more accurate diagnoses than individuals. And there’s a new target for reducing sodium consumption.
Amazon Alexa
Apple Podcasts
Google Podcasts
Spotify

Recommended Reading

What I learned from Navy SEALs about resilience
MDedge Psychiatry
Mediterranean diet cut Parkinson’s risk
MDedge Psychiatry
500 Women in Medicine: Part II
MDedge Psychiatry
A prescription for medicine’s gender inequality
MDedge Psychiatry
Parental leave inequities: Kirti Magudia and Thomas Ng, Part I
MDedge Psychiatry
Trump targets abortion by denying family planning funds
MDedge Psychiatry
Online vitriol’s expansion into doctor discussion sites
MDedge Psychiatry
Will having fewer primary care physicians shorten Americans’ lifespans?
MDedge Psychiatry
Cancer-battling breath, Zombie Bambi, and hops as health food
MDedge Psychiatry
Achieving recovery not a one-size-fits-all proposition
MDedge Psychiatry